Loading…
Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic
The pandemic of COVID‐19 is a global challenge for health care, and dermatologists are not standing apart from trying to meet this challenge. The European Academy of Dermatology and Venereology (EADV) has collected recommendations from its Task Forces (TFs) related to COVID‐19. The Journal of the EA...
Saved in:
| Published in: | Journal of the European Academy of Dermatology and Venereology 2020-08, Vol.34 (8), p.1666-1671 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4150-bce6be546f80f7be057f236fc586a33b329e0fb26f56db6bc5141f87aa1386c83 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4150-bce6be546f80f7be057f236fc586a33b329e0fb26f56db6bc5141f87aa1386c83 |
| container_end_page | 1671 |
| container_issue | 8 |
| container_start_page | 1666 |
| container_title | Journal of the European Academy of Dermatology and Venereology |
| container_volume | 34 |
| creator | Chernyshov, P.V. Tomas‐Aragones, L. Augustin, M. Svensson, A. Bewley, A. Poot, F. Szepietowski, J.C. Marron, S.E. Manolache, L. Pustisek, N. Suru, A. Salavastru, C.M. Blome, C. Salek, M.S. Abeni, D. Sampogna, F. Dalgard, F. Linder, D. Evers, A.W.M. Finlay, A.Y. |
| description | The pandemic of COVID‐19 is a global challenge for health care, and dermatologists are not standing apart from trying to meet this challenge. The European Academy of Dermatology and Venereology (EADV) has collected recommendations from its Task Forces (TFs) related to COVID‐19. The Journal of the EADV has established a COVID‐19 Special Forum giving free access to related articles. The psychosocial effects of the pandemic, an increase in contact dermatitis and several other skin diseases because of stress, disinfectants and protective equipment use, especially in healthcare workers, the temporary limited access to dermatologic care, the dilemma whether or not to pause immunosuppressive therapy, and, finally, the occurrence of skin lesions in patients infected by COVID‐19 all contribute to significant quality of life (QoL) impairment. Here, we present detailed recommendations of the EADV TF on QoL and patient‐oriented outcomes on how to improve QoL in dermatologic patients during the COVID‐19 pandemic for several different groups of patients and for the general population. |
| doi_str_mv | 10.1111/jdv.16720 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7301033</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2410360378</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4150-bce6be546f80f7be057f236fc586a33b329e0fb26f56db6bc5141f87aa1386c83</originalsourceid><addsrcrecordid>eNp1Us1u1DAQthCILoUDL4B8pIe0dpw4zgWp2m2haKUtUtmr5TjjrUsSb-2kaG88Am_HnSfB2ZQFDvgy8sz3Z3kQek3JKY3n7K5-OKW8SMkTNKMZFwkjgj1FM1KmPCnLvDxCL0K4I4RQmovn6IilWSloKmbox7ULtreuw6FXPbTQ9dgZ3N8Cvhi824Lq8LlWNbS7sb8A36reNW6zw6qr8Ro68DDdb1T4gi-d14Cj3KdBNbbfk5bWwB59rXo7Gqz8WKDGq6HXroUwEu7_EJqRYEMY4sR2uD6YWo23k0bA9eBtt9knna_WV4uf377TMo67mNXql-iZUU2AV4_1GH2-vLiZf0iWq_dX8_NlojOak6TSwCvIM24EMUUFJC9MyrjRueCKsYqlJRBTpdzkvK54pXOaUSMKpSgTXAt2jN5NutuhaqHWMZpXjdx62yq_k05Z-e-ks7dy4x5kwQgljEWBt48C3t3HB_eytUFD06gO3BBkmkUYJ6wYvU4mqPYuBA_mYEOJHBdBxkWQ-0WI2Dd_5zogf_98BJxNgK-2gd3_leTHxXqS_AUZysOQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2410360378</pqid></control><display><type>article</type><title>Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic</title><source>Wiley Online Library</source><creator>Chernyshov, P.V. ; Tomas‐Aragones, L. ; Augustin, M. ; Svensson, A. ; Bewley, A. ; Poot, F. ; Szepietowski, J.C. ; Marron, S.E. ; Manolache, L. ; Pustisek, N. ; Suru, A. ; Salavastru, C.M. ; Blome, C. ; Salek, M.S. ; Abeni, D. ; Sampogna, F. ; Dalgard, F. ; Linder, D. ; Evers, A.W.M. ; Finlay, A.Y.</creator><creatorcontrib>Chernyshov, P.V. ; Tomas‐Aragones, L. ; Augustin, M. ; Svensson, A. ; Bewley, A. ; Poot, F. ; Szepietowski, J.C. ; Marron, S.E. ; Manolache, L. ; Pustisek, N. ; Suru, A. ; Salavastru, C.M. ; Blome, C. ; Salek, M.S. ; Abeni, D. ; Sampogna, F. ; Dalgard, F. ; Linder, D. ; Evers, A.W.M. ; Finlay, A.Y.</creatorcontrib><description>The pandemic of COVID‐19 is a global challenge for health care, and dermatologists are not standing apart from trying to meet this challenge. The European Academy of Dermatology and Venereology (EADV) has collected recommendations from its Task Forces (TFs) related to COVID‐19. The Journal of the EADV has established a COVID‐19 Special Forum giving free access to related articles. The psychosocial effects of the pandemic, an increase in contact dermatitis and several other skin diseases because of stress, disinfectants and protective equipment use, especially in healthcare workers, the temporary limited access to dermatologic care, the dilemma whether or not to pause immunosuppressive therapy, and, finally, the occurrence of skin lesions in patients infected by COVID‐19 all contribute to significant quality of life (QoL) impairment. Here, we present detailed recommendations of the EADV TF on QoL and patient‐oriented outcomes on how to improve QoL in dermatologic patients during the COVID‐19 pandemic for several different groups of patients and for the general population.</description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.16720</identifier><identifier>PMID: 32498128</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Advisory Committees ; Betacoronavirus ; Coronavirus Infections - epidemiology ; Coronavirus Infections - psychology ; COVID-19 ; Dermatology - organization & administration ; Europe - epidemiology ; Guidelines and Position Statements ; Humans ; Infection Control - organization & administration ; Infectious Disease Transmission, Patient-to-Professional - prevention & control ; Pandemics ; Periodicals as Topic ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - psychology ; Position Statement ; Quality of Life ; SARS-CoV-2 ; Skin Diseases - etiology ; Skin Diseases - psychology ; Skin Diseases - therapy ; Societies, Medical ; Venereology - organization & administration</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2020-08, Vol.34 (8), p.1666-1671</ispartof><rights>2020 European Academy of Dermatology and Venereology</rights><rights>2020 European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4150-bce6be546f80f7be057f236fc586a33b329e0fb26f56db6bc5141f87aa1386c83</citedby><cites>FETCH-LOGICAL-c4150-bce6be546f80f7be057f236fc586a33b329e0fb26f56db6bc5141f87aa1386c83</cites><orcidid>0000-0002-4612-5699 ; 0000-0002-4026-8728 ; 0000-0002-7624-3290 ; 0000-0002-2821-7418 ; 0000-0001-5891-628X ; 0000-0003-2143-1646 ; 0000-0003-0766-6342 ; 0000-0002-0305-3146 ; 0000-0001-7275-4651</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjdv.16720$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjdv.16720$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,315,786,790,891,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32498128$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chernyshov, P.V.</creatorcontrib><creatorcontrib>Tomas‐Aragones, L.</creatorcontrib><creatorcontrib>Augustin, M.</creatorcontrib><creatorcontrib>Svensson, A.</creatorcontrib><creatorcontrib>Bewley, A.</creatorcontrib><creatorcontrib>Poot, F.</creatorcontrib><creatorcontrib>Szepietowski, J.C.</creatorcontrib><creatorcontrib>Marron, S.E.</creatorcontrib><creatorcontrib>Manolache, L.</creatorcontrib><creatorcontrib>Pustisek, N.</creatorcontrib><creatorcontrib>Suru, A.</creatorcontrib><creatorcontrib>Salavastru, C.M.</creatorcontrib><creatorcontrib>Blome, C.</creatorcontrib><creatorcontrib>Salek, M.S.</creatorcontrib><creatorcontrib>Abeni, D.</creatorcontrib><creatorcontrib>Sampogna, F.</creatorcontrib><creatorcontrib>Dalgard, F.</creatorcontrib><creatorcontrib>Linder, D.</creatorcontrib><creatorcontrib>Evers, A.W.M.</creatorcontrib><creatorcontrib>Finlay, A.Y.</creatorcontrib><title>Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>The pandemic of COVID‐19 is a global challenge for health care, and dermatologists are not standing apart from trying to meet this challenge. The European Academy of Dermatology and Venereology (EADV) has collected recommendations from its Task Forces (TFs) related to COVID‐19. The Journal of the EADV has established a COVID‐19 Special Forum giving free access to related articles. The psychosocial effects of the pandemic, an increase in contact dermatitis and several other skin diseases because of stress, disinfectants and protective equipment use, especially in healthcare workers, the temporary limited access to dermatologic care, the dilemma whether or not to pause immunosuppressive therapy, and, finally, the occurrence of skin lesions in patients infected by COVID‐19 all contribute to significant quality of life (QoL) impairment. Here, we present detailed recommendations of the EADV TF on QoL and patient‐oriented outcomes on how to improve QoL in dermatologic patients during the COVID‐19 pandemic for several different groups of patients and for the general population.</description><subject>Advisory Committees</subject><subject>Betacoronavirus</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - psychology</subject><subject>COVID-19</subject><subject>Dermatology - organization & administration</subject><subject>Europe - epidemiology</subject><subject>Guidelines and Position Statements</subject><subject>Humans</subject><subject>Infection Control - organization & administration</subject><subject>Infectious Disease Transmission, Patient-to-Professional - prevention & control</subject><subject>Pandemics</subject><subject>Periodicals as Topic</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - psychology</subject><subject>Position Statement</subject><subject>Quality of Life</subject><subject>SARS-CoV-2</subject><subject>Skin Diseases - etiology</subject><subject>Skin Diseases - psychology</subject><subject>Skin Diseases - therapy</subject><subject>Societies, Medical</subject><subject>Venereology - organization & administration</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1Us1u1DAQthCILoUDL4B8pIe0dpw4zgWp2m2haKUtUtmr5TjjrUsSb-2kaG88Am_HnSfB2ZQFDvgy8sz3Z3kQek3JKY3n7K5-OKW8SMkTNKMZFwkjgj1FM1KmPCnLvDxCL0K4I4RQmovn6IilWSloKmbox7ULtreuw6FXPbTQ9dgZ3N8Cvhi824Lq8LlWNbS7sb8A36reNW6zw6qr8Ro68DDdb1T4gi-d14Cj3KdBNbbfk5bWwB59rXo7Gqz8WKDGq6HXroUwEu7_EJqRYEMY4sR2uD6YWo23k0bA9eBtt9knna_WV4uf377TMo67mNXql-iZUU2AV4_1GH2-vLiZf0iWq_dX8_NlojOak6TSwCvIM24EMUUFJC9MyrjRueCKsYqlJRBTpdzkvK54pXOaUSMKpSgTXAt2jN5NutuhaqHWMZpXjdx62yq_k05Z-e-ks7dy4x5kwQgljEWBt48C3t3HB_eytUFD06gO3BBkmkUYJ6wYvU4mqPYuBA_mYEOJHBdBxkWQ-0WI2Dd_5zogf_98BJxNgK-2gd3_leTHxXqS_AUZysOQ</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Chernyshov, P.V.</creator><creator>Tomas‐Aragones, L.</creator><creator>Augustin, M.</creator><creator>Svensson, A.</creator><creator>Bewley, A.</creator><creator>Poot, F.</creator><creator>Szepietowski, J.C.</creator><creator>Marron, S.E.</creator><creator>Manolache, L.</creator><creator>Pustisek, N.</creator><creator>Suru, A.</creator><creator>Salavastru, C.M.</creator><creator>Blome, C.</creator><creator>Salek, M.S.</creator><creator>Abeni, D.</creator><creator>Sampogna, F.</creator><creator>Dalgard, F.</creator><creator>Linder, D.</creator><creator>Evers, A.W.M.</creator><creator>Finlay, A.Y.</creator><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4612-5699</orcidid><orcidid>https://orcid.org/0000-0002-4026-8728</orcidid><orcidid>https://orcid.org/0000-0002-7624-3290</orcidid><orcidid>https://orcid.org/0000-0002-2821-7418</orcidid><orcidid>https://orcid.org/0000-0001-5891-628X</orcidid><orcidid>https://orcid.org/0000-0003-2143-1646</orcidid><orcidid>https://orcid.org/0000-0003-0766-6342</orcidid><orcidid>https://orcid.org/0000-0002-0305-3146</orcidid><orcidid>https://orcid.org/0000-0001-7275-4651</orcidid></search><sort><creationdate>202008</creationdate><title>Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic</title><author>Chernyshov, P.V. ; Tomas‐Aragones, L. ; Augustin, M. ; Svensson, A. ; Bewley, A. ; Poot, F. ; Szepietowski, J.C. ; Marron, S.E. ; Manolache, L. ; Pustisek, N. ; Suru, A. ; Salavastru, C.M. ; Blome, C. ; Salek, M.S. ; Abeni, D. ; Sampogna, F. ; Dalgard, F. ; Linder, D. ; Evers, A.W.M. ; Finlay, A.Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4150-bce6be546f80f7be057f236fc586a33b329e0fb26f56db6bc5141f87aa1386c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Advisory Committees</topic><topic>Betacoronavirus</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - psychology</topic><topic>COVID-19</topic><topic>Dermatology - organization & administration</topic><topic>Europe - epidemiology</topic><topic>Guidelines and Position Statements</topic><topic>Humans</topic><topic>Infection Control - organization & administration</topic><topic>Infectious Disease Transmission, Patient-to-Professional - prevention & control</topic><topic>Pandemics</topic><topic>Periodicals as Topic</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - psychology</topic><topic>Position Statement</topic><topic>Quality of Life</topic><topic>SARS-CoV-2</topic><topic>Skin Diseases - etiology</topic><topic>Skin Diseases - psychology</topic><topic>Skin Diseases - therapy</topic><topic>Societies, Medical</topic><topic>Venereology - organization & administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chernyshov, P.V.</creatorcontrib><creatorcontrib>Tomas‐Aragones, L.</creatorcontrib><creatorcontrib>Augustin, M.</creatorcontrib><creatorcontrib>Svensson, A.</creatorcontrib><creatorcontrib>Bewley, A.</creatorcontrib><creatorcontrib>Poot, F.</creatorcontrib><creatorcontrib>Szepietowski, J.C.</creatorcontrib><creatorcontrib>Marron, S.E.</creatorcontrib><creatorcontrib>Manolache, L.</creatorcontrib><creatorcontrib>Pustisek, N.</creatorcontrib><creatorcontrib>Suru, A.</creatorcontrib><creatorcontrib>Salavastru, C.M.</creatorcontrib><creatorcontrib>Blome, C.</creatorcontrib><creatorcontrib>Salek, M.S.</creatorcontrib><creatorcontrib>Abeni, D.</creatorcontrib><creatorcontrib>Sampogna, F.</creatorcontrib><creatorcontrib>Dalgard, F.</creatorcontrib><creatorcontrib>Linder, D.</creatorcontrib><creatorcontrib>Evers, A.W.M.</creatorcontrib><creatorcontrib>Finlay, A.Y.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chernyshov, P.V.</au><au>Tomas‐Aragones, L.</au><au>Augustin, M.</au><au>Svensson, A.</au><au>Bewley, A.</au><au>Poot, F.</au><au>Szepietowski, J.C.</au><au>Marron, S.E.</au><au>Manolache, L.</au><au>Pustisek, N.</au><au>Suru, A.</au><au>Salavastru, C.M.</au><au>Blome, C.</au><au>Salek, M.S.</au><au>Abeni, D.</au><au>Sampogna, F.</au><au>Dalgard, F.</au><au>Linder, D.</au><au>Evers, A.W.M.</au><au>Finlay, A.Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2020-08</date><risdate>2020</risdate><volume>34</volume><issue>8</issue><spage>1666</spage><epage>1671</epage><pages>1666-1671</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><notes>Funding sources</notes><notes>AYF is joint copyright owner of the DLQI, CDLQI, IDQoL, DFI, FDLQI, TQoL, FROM‐16, PFI, MLCDP and other quality of life measures: Cardiff University and AYF receive royalties from the use of these measures. AYF has received honoraria for advisory boards: Sanofi, Novartis, USB Pharma. JCS reports personal fees from Abbvie, Leo Pharma, Novartis, Pierre‐Fabre, Menlo Therapeutics, Sienna Biopharmaceuticals, Trevi, Janssen, Sunfarm, Elli‐Lilly, Berlin‐Chemie Mennarini, Merck, Regeneron, Sanofi‐Genzyme, Amgen, Boehringer Ingelheim, Galapagos, InflaRX, Pfizer, UCB, Incyte and Helm, outside the submitted work. AB has received travel grants or acts as an ad hoc consultant for Abbvie, Almirall, Galderma, Janssen, Lily, Leo Pharma, Novartis, Sanofi and UCB. MSS is joint copyright owner of TQoL, FROM‐16, PFI and MLCD: Cardiff University and MSS receive royalties from the use of these measures. MSS has received unrestricted educational grant from Celgene, European Hematology Association, GSK and Centre for Innovative Regulatory Science (CIRS). CB reports grants and personal fees from Celgene, grants from Bauerfeind, outside the submitted work. Other authors reported no conflicts of interests.</notes><notes>Conflict of interest</notes><notes>None declared.</notes><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>ObjectType-Instructional Material/Guideline-3</notes><notes>content type line 23</notes><abstract>The pandemic of COVID‐19 is a global challenge for health care, and dermatologists are not standing apart from trying to meet this challenge. The European Academy of Dermatology and Venereology (EADV) has collected recommendations from its Task Forces (TFs) related to COVID‐19. The Journal of the EADV has established a COVID‐19 Special Forum giving free access to related articles. The psychosocial effects of the pandemic, an increase in contact dermatitis and several other skin diseases because of stress, disinfectants and protective equipment use, especially in healthcare workers, the temporary limited access to dermatologic care, the dilemma whether or not to pause immunosuppressive therapy, and, finally, the occurrence of skin lesions in patients infected by COVID‐19 all contribute to significant quality of life (QoL) impairment. Here, we present detailed recommendations of the EADV TF on QoL and patient‐oriented outcomes on how to improve QoL in dermatologic patients during the COVID‐19 pandemic for several different groups of patients and for the general population.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>32498128</pmid><doi>10.1111/jdv.16720</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4612-5699</orcidid><orcidid>https://orcid.org/0000-0002-4026-8728</orcidid><orcidid>https://orcid.org/0000-0002-7624-3290</orcidid><orcidid>https://orcid.org/0000-0002-2821-7418</orcidid><orcidid>https://orcid.org/0000-0001-5891-628X</orcidid><orcidid>https://orcid.org/0000-0003-2143-1646</orcidid><orcidid>https://orcid.org/0000-0003-0766-6342</orcidid><orcidid>https://orcid.org/0000-0002-0305-3146</orcidid><orcidid>https://orcid.org/0000-0001-7275-4651</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0926-9959 |
| ispartof | Journal of the European Academy of Dermatology and Venereology, 2020-08, Vol.34 (8), p.1666-1671 |
| issn | 0926-9959 1468-3083 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7301033 |
| source | Wiley Online Library |
| subjects | Advisory Committees Betacoronavirus Coronavirus Infections - epidemiology Coronavirus Infections - psychology COVID-19 Dermatology - organization & administration Europe - epidemiology Guidelines and Position Statements Humans Infection Control - organization & administration Infectious Disease Transmission, Patient-to-Professional - prevention & control Pandemics Periodicals as Topic Pneumonia, Viral - epidemiology Pneumonia, Viral - psychology Position Statement Quality of Life SARS-CoV-2 Skin Diseases - etiology Skin Diseases - psychology Skin Diseases - therapy Societies, Medical Venereology - organization & administration |
| title | Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T12%3A23%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Position%20statement%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology%20Task%20Force%20on%20Quality%20of%20Life%20and%20Patient%20Oriented%20Outcomes%20on%20quality%20of%20life%20issues%20in%20dermatologic%20patients%20during%20the%20COVID%E2%80%9019%20pandemic&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Chernyshov,%20P.V.&rft.date=2020-08&rft.volume=34&rft.issue=8&rft.spage=1666&rft.epage=1671&rft.pages=1666-1671&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.16720&rft_dat=%3Cproquest_pubme%3E2410360378%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4150-bce6be546f80f7be057f236fc586a33b329e0fb26f56db6bc5141f87aa1386c83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2410360378&rft_id=info:pmid/32498128&rfr_iscdi=true |